- Funding enables AMSilk to accelerate industrial scale-up and expand commercial operations of bio-fabricated silk protein materials
- Financing led by existing investors ATHOS (AT Newtec) with participation from Novo Holdings, Cargill, and MIG Capital.
Munich, 4. April, 2023: AMSilk GmbH (“AMSilk”), the world’s first industrial supplier of bio-fabricated silk protein materials, today announced it has successfully raised an additional EUR 25 million in an extended Series C financing led by existing investor ATHOS (AT Newtec) with participation from Novo Holdings, Cargill, and MIG Capital.
AMSilk’s outstanding technology platform, based on silk proteins, produces bio-fabricated materials that can be utilized across a variety of applications such as textile fibers, medical devices and consumer goods.
Proceeds from the financing will enable AMSilk to accelerate the ongoing scale-up of its industrialization and commercialization projects worldwide, to meet the ever-increasing demand for AMSilk’s innovative materials.